ENvue Medical, Inc. FEED
Medical, Inc. (the "Company"), formerly known as NanoVibronix, Inc., was incorporated as a Delaware corporation in
October 2003. In December 2025, the Company changed its name from NanoVibronix, Inc. to ENvue Medical, Inc. Prior to such a name
change, on February 14, 2025, the Company consummated and completed its merger (the "Merger") pursuant to the Agreement
and Plan of Merger, dated as of February 14, 2025 (the "Merger Agreement"), as further described herein. Following the
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by segment
- Nano Vibronix
- ENvue
| Segment | FY2025 |
|---|---|
| Nano Vibronix | $1.9M |
| ENvue | $696.0K |
As the company reported it, from the “SCHEDULE OF SEGMENT INFORMATION (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | $2.6M | $2.3M | $752.0K | $1.7M | $623.0K | $530.0K | $318.0K | $239.0K | $229.0K |
| Cost of revenue | $2.4M | $1.1M | $746.0K | $585.0K | $925.0K | $409.0K | $249.0K | $158.0K | $88.0K | $88.0K |
| Gross profit | $153.0K | $1.5M | $1.5M | $167.0K | $770.0K | $214.0K | $281.0K | $160.0K | $151.0K | $141.0K |
| R&D | $1.8M | $909.0K | $185.0K | $283.0K | $293.0K | $171.0K | $514.0K | $614.0K | $693.0K | $584.0K |
| SG&A | $7.6M | $3.5M | $3.9M | $3.9M | $5.1M | $3.8M | $3.8M | $2.6M | $2.1M | $1.4M |
| Total operating expenses | $23.0M | $5.1M | $5.0M | $5.2M | $6.5M | $4.9M | $5.4M | $4.5M | $3.2M | $2.5M |
| Operating income | -$22.9M | -$3.6M | -$3.4M | -$5.0M | -$5.7M | -$4.7M | -$5.2M | -$4.3M | -$3.1M | -$2.3M |
| Interest expense | — | $135.0K | $135.0K | $347.0K | — | $147.0K | $15.0K | — | — | — |
| Pre-tax income | -$18.5M | -$3.7M | -$3.7M | -$5.4M | -$14.2M | -$4.3M | -$5.8M | -$4.3M | -$4.9M | -$2.7M |
| Income tax | $307.0K | $19.0K | $29.0K | $35.0K | $32.0K | $15.0K | $17.0K | $127.0K | $38.0K | $117.0K |
| Net income | -$18.2M | -$3.7M | -$3.7M | -$5.4M | -$14.3M | -$4.3M | -$5.8M | -$4.2M | -$5.0M | -$2.8M |
| EPS, basic | -26.69 | -137.30 | -23.32 | -3.84 | -11.35 | — | — | — | — | — |
| EPS, diluted | -26.69 | -137.30 | -23.32 | -3.84 | -0.57 | -0.42 | -0.83 | -0.64 | -1.17 | -0.62 |
| Shares, diluted (wtd. avg.) | 628,534 | 26,985 | 159,105 | 1.4M | 1.3M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.2M | $752.0K | $3.3M | $2.7M | $7.7M | $7.1M | $1.3M | $896.0K | $4.4M | $106.0K |
| Receivables | $289.0K | $98.0K | $318.0K | $9.0K | $200.0K | $25.0K | $111.0K | $95.0K | $24.0K | $6.0K |
| Inventory | $2.3M | $2.2M | $2.7M | $2.2M | $175.0K | $145.0K | $121.0K | $144.0K | $76.0K | $67.0K |
| Total current assets | $7.3M | $3.3M | $6.5M | $5.6M | $8.3M | $8.0M | $1.8M | $1.2M | $4.5M | $221.0K |
| Property, plant and equipment | $119.0K | $9.0K | $7.0K | $7.0K | $5.0K | $4.0K | $4.0K | $8.0K | $5.0K | $11.0K |
| Goodwill | $29.1M | — | — | — | — | — | — | — | — | — |
| Other intangibles | $4.4M | — | — | — | — | — | — | — | — | — |
| Total assets | $41.1M | $3.6M | $6.7M | $5.9M | $8.6M | $8.2M | $2.0M | $1.6M | $4.9M | $494.0K |
| Accounts payable | $719.0K | $47.0K | $138.0K | $66.0K | $87.0K | $144.0K | $129.0K | $193.0K | $168.0K | $82.0K |
| Total current liabilities | $6.7M | $2.7M | $2.5M | $2.3M | $1.9M | $2.9M | $409.0K | $640.0K | $797.0K | $565.0K |
| Total liabilities | $7.6M | $3.0M | $2.7M | $2.6M | $2.3M | $5.8M | $688.0K | $1.1M | — | — |
| Retained earnings | -$90.5M | -$69.8M | -$66.1M | -$62.4M | -$56.9M | -$42.7M | -$38.3M | -$32.5M | -$28.4M | -$22.6M |
| Total equity | $33.5M | $627.0K | $4.0M | $3.2M | $6.3M | $2.4M | $1.3M | $463.0K | $3.6M | -$2.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.4M | -$2.5M | -$3.6M | -$7.0M | -$4.4M | -$3.4M | -$3.9M | -$3.5M | -$2.2M | -$1.5M |
| Depreciation and amortisation | $897.0K | $1.0K | $1.0K | $1.0K | $2.0K | $2.0K | $4.0K | $6.0K | $5.0K | $7.0K |
| Stock-based compensation | — | $356.0K | $293.0K | $354.0K | $382.0K | $376.0K | $1.8M | $889.0K | $800.0K | $508.0K |
| Capital expenditure | $60.0K | $3.0K | $1.0K | $3.0K | $3.0K | $2.0K | — | $8.0K | — | $8.0K |
| Investing cash flow | $88.0K | -$3.0K | -$1.0K | -$3.0K | -$3.0K | -$2.0K | — | -$8.0K | — | -$8.0K |
| Financing cash flow | $12.8M | $1.0K | $4.2M | $2.1M | $4.6M | $9.5M | $4.3M | $94.0K | $6.4M | $33.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-016871.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $229.0K | $239.0K | $318.0K | $530.0K | $623.0K | $1.7M | $752.0K | $2.3M | $2.6M | $2.6M |
| Gross profit | $141.0K | $151.0K | $160.0K | $281.0K | $214.0K | $770.0K | $167.0K | $1.5M | $1.5M | $153.0K |
| Net income | -$2.8M | -$5.0M | -$4.2M | -$5.8M | -$4.3M | -$14.3M | -$5.4M | -$3.7M | -$3.7M | -$18.2M |
Recent filings and events
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Officer or director change Item 5.02
- Material agreement signed Item 1.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed Item 5.03
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3842
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $159.78B | 57.5x | 20.5% |
| EW | Edwards Lifesciences Corp | $51.34B | 48.7x | 11.5% |
| STE | STERIS plc | $22.63B | 29.3x | 8.7% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $18.80B | 27.8x | 7.2% |
| ALGN | ALIGN TECHNOLOGY INC | $10.98B | 27.3x | 0.9% |
| MSA | MSA Safety Inc | $7.03B | 25.7x | 3.7% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $1.90B | — | 27.1% |
| CDRE | Cadre Holdings, Inc. | $1.28B | 29.4x | 7.5% |